Ask AI
ProCE Banner Activity

Practical Considerations for Using PARP Inhibitors in Ovarian Cancer: Key ESMO Congress Updates

Clinical Thought
Two expert gynecologic oncologists discuss how to optimally use PARP inhibitors to treat patients with ovarian cancer.

Released: October 19, 2022

Continue Activity View Activity

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

GlaxoSmithKline

Karyopharm Therapeutics Inc.

Merck Sharp & Dohme Corp.

Faculty Disclosure

Primary Author

Alexandra Leary, MD, PhD

President, GINECO Group
Co-Director, Department of Medical Oncology
Medical Oncologist Gynecology
Team Leader, Gynecologic Translational Research Lab, INSERM u981
Institut Gustave Roussy
Villejuif, France

Alexandra Leary, MD, PhD: consultant/advisor/speaker: Ability, AstraZeneca, Clovis, GlaxoSmithKline, Merck Sharp and Dohme, Zentalis; researcher: Apmonia; AstraZeneca.

Domenica Lorusso, MD, PhD, Prof

Head of Gynecological Oncology Medical Unit
Humanitas San Pio X
Full Professor of Obtetrics and Gynecology
Department of Biomedical Sciences, Humanitas University
Milan, Italy

Domenica Lorusso, MD, PhD: consultant/advisor/speaker: AstraZeneca, Clovis, Genmab, GlaxoSmithKline, Immunogen, Merck Sharp and Dohme, Novartis, Seagen, Sutro.